AstraZeneca To Shut Indian API Site
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca is shuttering its Indian active pharmaceutical ingredient unit in Yelahanka, Bangalore in a move the UK-based firm says was triggered by low export demand for the key product made there.